BioSpace News Archive

Policy

U.S. Government Alleges Regeneron Used Kickbacks to Boost Eylea Sales

Regeneron Pharmaceuticals said it will vigorously defend federal charges that it was involved in a kickback scheme to bolster sales of its blockbuster macular degeneration drug, Eylea.

June 25, 2020
·
3 min read
·
Alex Keown
Drug Development

Biopharma Update on the Novel Coronavirus: June 26

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.

June 25, 2020
·
3 min read
·
BioSpace Editorial Staff
Business

Sanofi Considering Additional Restructuring and Up to 1,000 Job Cuts

According to a brief report by Reuters, the drug company plans to hold meetings with staff representatives tomorrow and Monday of next week to describe a restructuring plan, according to four sources familiar with the matter.

June 25, 2020
·
5 min read
·
Mark Terry
Business

Regenerative Medicine Needs a New, Digital Supply Chain

The supply chain that exists for traditional pharmaceuticals is woefully insufficient for regenerative medicine, according to Robert Lechich, principal manufacturing and supply chain consultant for Global OT/IT – Quality Services.

June 25, 2020
·
5 min read
·
Gail Dutton
Business

BioSpace Movers & Shakers, June 26

Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.

June 25, 2020
·
5 min read
·
Alex Keown
Policy

Novartis, Current and Former Units Agree to Pay More than $346 Million to Settle U.S. Bribery Charges

Novartis, Novartis Hellas and Alcon Inc. have agreed to pay a total of more than $346 million to settle bribery charges under the Foreign Corrupt Practices Act (FCPA), which is a U.S. anti-bribery law.

June 25, 2020
·
2 min read
·
Ellen Bombela
Deals

NantKwest Announces Pricing of Public Offering of Common Stock - June 25, 2020

NantKwest, Inc., a clinical-stage, natural killer cell-based therapeutics company, announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock.

June 25, 2020
·
3 min read
Deals

ERYTECH extends its cash horizon by implementing a convertible bond financing

Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached

June 25, 2020
·
21 min read
Drug Development

Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study

Moberg Pharma AB announces that MOB-015 met the primary endpoint in the European Phase 3 study including 452 onychomycosis patients, showing non-inferiority versus topical ciclopirox.

June 25, 2020
·
4 min read
Deals

Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline

Lead ‘OncoMimics’ candidate EO2401 planned to start first clinical trials for Glioblastoma and Adrenal Tumors during mid-2020

June 25, 2020
·
5 min read